Cold agglutinin disease (CAD) is a rare subtype of autoimmune haemolytic anaemia (AIHA) where autoantibodies, predominantly of the IgM class, bind to red blood cells at reduced temperatures. This ...
Enjaymo is the first-and-only approved therapeutic option approved for hemolytic anemia in adult patients with cold agglutinin disease Enjaymo is currently the only approved treatment for CAD and is a ...
/ -- Autoimmune hemolytic anemia (AIHA) treatment encompasses a range of therapeutic strategies aimed at mitigating the immune system's attack on red blood cells, thereby alleviating anemia and ...
In this prospective cohort study, CD19-directed chimeric antigen receptor (CAR) T-cell therapy was found to elicit a complete response in eleven patients with autoimmune hemolytic anemia who had ...
SOUTH SAN FRANCISCO, Calif., Jan. 20, 2026 /PRNewswire/ -- Ouro Medicines, a clinical stage biotechnology company developing immune reset therapeutics for people living with chronic, immune-mediated ...
Hosted on MSN
Hemolytic anemia causes and treatment
Hemolytic anemia occurs when red blood cells are destroyed faster than they can be replaced. The loss of red blood cells means that fewer are available to carry oxygen and nutrients to tissues or ...
Microangiopathic hemolytic anemia (MAHA) occurs when turbulence in the blood destroys red blood cells. This leads to symptoms such as tiredness and shortness of breath. Certain treatments are ...
Dr. Florence H. Porterfield (Medicine): A 71-year-old woman was admitted to this hospital because of refractory hemolytic anemia. The patient, who had recurrent breast cancer and diffuse cutaneous ...
Enjaymo is the first-and-only approved therapeutic option approved for hemolytic anemia in adult patients with cold agglutinin disease Paris, November 17, 2022. The European Commission (EC) has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results